Posted recently We forget sometimes, the unlimited potential of Behl in oh so many different fronts. Specific mention of Spirulina and state of the art closed loop growing system.
Clearwater, FL, Dec 02, 2009 (WORLD STOCK WIRE via COMTEX) -- PanGenex Corporation (OTC Pink Sheets: PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that Company is actively identifying new product development opportunities that will initially focus on the immune-boosting properties of spirulina. The Company recently entered into a licensing agreement to begin producing the highest quality, purest form of spirulina using a state-of-the-art closed loop growing system.
With a 60% protein content, spirulina is a fresh water algae that contains more protein than red meat and soy, combined. Spirulina also contains high concentrations of the antioxidant beta carotene, iron, vitamin B-12, and the rare gamma-linolenic acid (GLA), an essential fatty acid for cellular health. Over the past 15 years, extensive research on spirulina support a growing world acceptance of the algae for use in dietary supplements. Scientists in the U.S., Japan and China have independently discovered that small amounts of spirulina, when added to animal feed, greatly helped animals resist infections.
"Research on spirulina continues to support the beneficial properties of this human 'superfood.' With our nation's overuse of antibiotics, prescribed medicines are increasingly becoming ineffective. All-natural remedies and dietary supplement sales are booming despite the national recession. We believe our entry into the spirulina market coincides with very attractive consumer healthy living trends. We are now working closely with our scientific advisors and product consultants to capitalize on the immune-boosting properties of Spirulina to develop a whole range of commercially viable products for the over-the-counter market," said John Stanton, Chairman of PanGenex.
About PanGenex Corporation
PanGenex pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels for review by the FDA without incidence. PanGenex products are currently sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet including: www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.
News 
Market Data 
Discover 
AI
